Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-10-10
2009-10-06
Blanchard, David J. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S006120, C435S007100, C530S387700
Reexamination Certificate
active
07598052
ABSTRACT:
The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with thyroid cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of thyroid cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications.
REFERENCES:
patent: 7319011 (2008-01-01), Riggins et al.
patent: 2005/0074798 (2005-04-01), Sukumar et al.
Tzelepi, Tsamandas, Vlotinou, Vagianos, and Scopa. Tight junctions in thyroid carcinogenesis: diverse expression of claudin-1, claudin-4, claudin-7 and occludin in thyroid neoplasms. Modern Pathology, 2008. vol. 21, pp. 22-30.
Lewin. Genes IV. 1990. Oxford University Press, p. 810.
Tanaka, Umeki, Yamamoto, Sugiyama, Noguchi, and Ohtaki. Immunohistochemical loss of thyroid peroxidase in papillary thyroid carcinoma: strong suppression of peroxidase gene expression. Journal of Pathology, 1996. vol. 179, pp. 89- 94.
Allander et al., “Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile” Cancer Res, 200161, 8624-8.
Baker, “The immune response to papillary thyroid cancer” J Clin Endocrinol Metab, 1995, 80, 3419-20.
Begum et al., “BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment” Mod Pathol, 2004, 17, 1359-63.
Bertucci et al., “Identification and validation of an ERBB2 gene expression signature in breast cancers” Oncogene, 2004, 23, 2564-75.
Bongarzone & Pieriotte, “The molecular basis of thyroid epithelial tumorigenesis” Tumori, 2003, 89, 514-6.
Bongarzone et al., “High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma” Oncogene, 1989, 4, 1457-62.
Bounacer et al., “High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation” Oncogene, 1997, 15, 1263-73.
Califano et al., “Analysis of Gene Expression Microarrays for Phenotype Classification” 2000 Proc. Int. Conf. Intell. Sys. Mol. Biol. 8 75-85.
Capella et al., “Ras oncogene mutations in thyroid tumors: polymerase chain reaction-restriction-fragment-length polymorphism analysis from paraffin-embedded tissues” Diagn Mol Pathol, 1996, 5, 45-52.
Cohen et al., “BRAF mutation in papillary thyroid carcinoma” J Natl Cancer Inst, 2003, 95, 625-7.
Demicco, Am J Clin Pathol, 2003120, 803, 2003.
Donghi et al., “Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland” J Clin Invest, 1993, 91, 1753-60.
Fagin, “Perspective: lessons learned from molecular genetic studies of thyroid cancer—insights into pathogenesis and tumor-specific therapeutic targets” Endocrinology, 2002, 143, 2025-8.
Giordano et al., “Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis” Am J Pathol, 2003, 162, 521-31.
Hedenfalk et al., “Gene-expression profiles in hereditary breast cancer” N Engl J Med, 2001344, 539-48, 2001.
Ho et al., “Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors” Cancer Res 2004, 64, 6915-8.
Huang et al., “Gene expression in papillary thyroid carcinoma reveals highly consistent profiles” Proc Natl Acad Sci U S A, 2001, 98, 15044-9.
Jazaeri et al., “Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers” J Natl Cancer Inst, 2002, 94, 990-1000.
Juhasz & Farid, “Immune response to papillary thyroid carcinoma” J Clin Endocrinol Metab, 1996, 81, 4175-6.
Karga et al., “Ras oncogene mutations in benign and malignant thyroid neoplasms” J Clin Endocrinol Metab, 1991, 73, 832-6.
Kimura et al., “High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma” Cancer Res, 2003, 63, 1454-7.
Kishida et al., “Enhancement of the aquaporin adipose gene expression by a peroxisome proliferator-activated receptor gamma” J Biol Chem 2001;276:48572.
Kroll et al., “PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma” Science 2000;289:1357.
Lowinger et al., “Design and discovery of small molecules targeting raf-1 kinase” Curr Pharm Des, 2002, 8, 2269-78.
Lynch et al., N Engl J Med, 2004, 35, 2129-39.
Lyons et al., “Discovery of a novel Raf kinase inhibitor” Endocr Relat Cancer, 2001, 8, 219-25.
Moretti et al., “Molecular pathogenesis of thyroid nodules and cancer” Baillieres Best Pract Res Clin Endocrinol Metab, 2000, 14, 517-39.
Namba et al., “Point mutations of ras oncogenes are an early event in thyroid tumorigenesis” Mol Endocrinol,1990, 4, 1474-9.
Nardone et al., “c-Met expression in tall cell variant papillary carcinoma of the thyroid” Cancer, 2003, 98, 1386-93.
Nikiforova et al., “BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas” J Clin Endocrinol Metab, 88, 5399-404, 2003.
Paez et al., “EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.” Science, 2004, 304, 1497-500.
Pavey et al., “Microarray expression profiling in melanoma reveals a BRAF mutation signature” Oncogene, 2004, 23, 4060-7.
Rabes et al., “Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications.” Clin Cancer Res, 2000, 6, 1093-103.
Rosty et al., “Overexpression of Si 00A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation.” 2002 Am. J. Pathol. 160 45-50.
Santoro et al., “Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype” J Clin Invest, 1992, 89, 1517-22.
Sawyers, “Opportunities and challenges in the development of kinase inhibitor therapy for cancer.” Genes Dev, 2003, 17, 2998-3010.
Schaefer et al., “Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3.” Cancer Res, 2004, 64, 3395-405.
Schwartz et al., “Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas.” Cancer Res, 2002, 62, 4722-9.
Segev et al., “Molecular pathogenesis of thyroid cancer” Surg Oncol, 2003, 12, 69-90.
Singer et al.,“Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma” J Natl Cancer Inst, 2003, 95, 484-6.
Soares et al., “BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.” Oncogene, 2003, 22, 4578-80.
Sorlie et al., “Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications” Proc Natl Acad Sci U S A, 2001 98, 10869-74.
Suarez et al., Oncogene, 1988 2(4):403-406.
Wasenius et al., “Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study.” Clin Cancer Res, 2003, 9, 68-75.
Welsh et al., “Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer” 2001 Proc. Natl. Acad. S
Giordano Thomas
Hanish Samir
Koenig Ronald
Kuick Rork
Nikiforov Yuri
Blanchard David J.
Casimir Jones S.C.
Gussow Anne M.
The Regents of the University of Michigan
LandOfFree
Expression profile of thyroid cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Expression profile of thyroid cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Expression profile of thyroid cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4064630